Treace Medical Concepts, Inc. (“Treace”) (NASDAQ:TMCI), a medical technology company driving a fundamental shift in the surgical treatment of hallux valgus (commonly known as bunions) through its Lapiplasty® 3D Bunion Correction™ Procedure, today announced treatment of the first patient in the MTA3D™ Adductoplasty® Clinical Study. The study will evaluate outcomes of the Adductoplasty® Procedure combined with the Lapiplasty® Procedure for patients in need of hallux valgus (bunion) and metatarsus adductus (midfoot) correction surgery. Midfoot deformities may occur in up to 30% of hallux valgus patients.1,2
Citigroup Maintains Neutral on SLM, Lowers Price Target to $16
Citigroup analyst Arren Cyganovich maintains SLM (NASDAQ:SLM) with a Neutral and lowers the price target from $17 to $16.
